Skip to content
Search

Latest Stories

Long A&E wait times led to almost 14,000 deaths last year in England: RCEM

Long A&E wait times led to almost 14,000 deaths last year in England: RCEM

The college has found that 65 per cent of people waiting 12 hours or more in A&E were patients waiting for a hospital bed

In 2023, almost 14,000 people in England are estimated to have died due to excessive waits in emergency departments, averaging more than 260 deaths per week, according to new figures from the Royal College of Emergency Medicine (RCEM).


The RCEM estimate is based on a large study of NHS patients published in the Emergency Medicine Journal in 2021, which found one excess death for every 72 patients who spent eight to 12 hours in an A&E department.

Following a Freedom of Information audit of NHS trusts, the college has found that 65 per cent of people waiting 12 hours or more in A&E were patients waiting for a hospital bed.

NHS data for England revealed that over 1.5 million patients waited 12 hours or more in major emergency departments last year. Based on the RCEM calculation, this indicates that over a million of those patients were waiting for a bed.

Looking solely at patients awaiting admission, the RCEM has calculated that an average of 268 excess deaths are likely to have occurred each week in 2023, which is just 17 fewer than in 2022, when a severe flu outbreak and Covid cases overwhelmed the NHS.

The college added that the figures didn’t include thousands of patients delayed in the back of ambulances, but they are also at risk of harm.

Dr Adrian Boyle, the president of the RCEM, expressed concern that prolonged waits continue to pose a serious risk of harm to patients.

“Small improvements in four-hour access standard performance are not meaningful when there are so many people staying more than 12 hours.

“Effort and money should go where the harm is greatest," he said, as quoted by The Guardian. 

Dr Boyle pointed out that due to the lack of hospital capacity, patients remain in emergency departments longer than required, and are being cared for by emergency department staff, often in clinically inappropriate areas like corridors or ambulances.

“Patients and staff should not bear the consequences of insufficient funding and under-resourcing. We cannot continue to face inequalities in care, avoidable delays and death,” he added.

However, an NHS spokesperson suggested that the cause of excess deaths could be attributed to various factors, emphasising the importance of the ONS experts to continue to analyse these factors.

Additionally, the spokesperson noted a significant increase in the demand for A&E services, indicating that attendances in February surged by 8.6 percent compared to the previous year, while emergency admissions increased by 7.7 percent.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less